NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Odonate Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $38.88 +0.22 (+0.57 %) (As of 07/8/2020 04:00 PM ET) Add Compare Share Today's Range$38.33Now: $38.88▼$39.6950-Day Range$29.46MA: $37.25▼$45.6352-Week Range$18.07Now: $38.88▼$46.50Volume45,400 shsAverage Volume110,980 shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/ABeta1.15 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.5 Analyst's Opinion Consensus RatingOdonate Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Odonate Therapeutics has a potential downside of 33.1% from its current price of $38.88.Amount of Analyst CoverageOdonate Therapeutics has received no research coverage in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesOdonate Therapeutics has received 149 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOdonate Therapeutics has received 199 “underperform” votes. (Add your “underperform” vote.)Community SentimentOdonate Therapeutics has received 57.18% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote “Outperform” if you believe ODT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOdonate Therapeutics does not currently pay a dividend.Dividend GrowthOdonate Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Odonate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders48.90% of the stock of Odonate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.78% of the stock of Odonate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Odonate Therapeutics are expected to grow in the coming year, from ($4.34) to ($3.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Odonate Therapeutics is -9.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Odonate Therapeutics is -9.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOdonate Therapeutics has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.05 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ODT Previous Symbol CUSIPN/A CIK1717452 Webwww.odonate.com Phone858-731-8180Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio6.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book7.68Profitability EPS (Most Recent Fiscal Year)($4.05) Net Income$-111,820,000.00 Net MarginsN/A Return on Equity-67.21% Return on Assets-58.26%Miscellaneous Employees117 Outstanding Shares32,110,000Market Cap$1.25 billion Next Earnings Date7/22/2020 (Estimated) OptionableNot Optionable NASDAQ:ODT Rates by TradingView Receive ODT News and Ratings via Email Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter. Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has increased by 49.9% and is now trading at $38.88. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for Odonate Therapeutics. When is Odonate Therapeutics' next earnings date? Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Odonate Therapeutics. How were Odonate Therapeutics' earnings last quarter? Odonate Therapeutics Inc (NASDAQ:ODT) posted its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.99) EPS for the quarter, topping the Zacks' consensus estimate of ($1.03) by $0.04. View Odonate Therapeutics' earnings history. What price target have analysts set for ODT? 1 brokers have issued twelve-month price targets for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' stock price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 33.1%. View analysts' price targets for Odonate Therapeutics. Has Odonate Therapeutics been receiving favorable news coverage? News headlines about ODT stock have been trending negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Odonate Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Odonate Therapeutics. Who are some of Odonate Therapeutics' key competitors? Some companies that are related to Odonate Therapeutics include Zai Lab (ZLAB), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Myokardia (MYOK), Nektar Therapeutics (NKTR), Biohaven Pharmaceutical (BHVN), Blueprint Medicines (BPMC), Evotec (EVTCY), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO) and FibroGen (FGEN). View all competitors. What other stocks do shareholders of Odonate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Bausch Health Companies (BHC), Five Prime Therapeutics (FPRX), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX) and Crispr Therapeutics (CRSP). Who are Odonate Therapeutics' key executives? Odonate Therapeutics' management team includes the following people: Mr. Kevin C. Tang, Chairman & CEO (Age 52)Mr. John G. Lemkey, Chief Operating Officer (Age 38)Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43) When did Odonate Therapeutics IPO? (ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager. What is Odonate Therapeutics' stock symbol? Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT." How do I buy shares of Odonate Therapeutics? Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Odonate Therapeutics' stock price today? One share of ODT stock can currently be purchased for approximately $38.88. How big of a company is Odonate Therapeutics? Odonate Therapeutics has a market capitalization of $1.25 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe. What is Odonate Therapeutics' official website? The official website for Odonate Therapeutics is www.odonate.com. How can I contact Odonate Therapeutics? Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected] This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
